A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
On December 13, 2024, we completed the previously announced business combination with Legacy Palvella in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Palvella, with Legacy Palvella surviving as our wholly owned subsidiary (such business combination, the Merger). In connection with the completion of the Merger, we changed our name from “Pieris Pharmaceuticals, Inc.” to “Palvella Therapeutics, Inc.,” and our business became primarily the business conducted by Legacy Palvella. We are now a clinical-stage biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Unless the context indicates otherwise, references in this section to the “Company,” “we,” “our,” “us” and “Palvella” refer, collectively, to Palvella Therapeutics, Inc.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 39M | 25M | 28M | 24M | 32M |
| Net Income | -35M | -25M | -33M | -46M | -37M | -28M |
| EPS | $-1.62 | $-19.85 | $-26.91 | $-49.10 | $-54.40 | $-44.80 |
| Free Cash Flow | 0 | -54M | -61M | -8.6M | -49M | -55M |
| ROIC | -34.0% | -91.7% | -123.0% | -90.1% | -86.4% | -55.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.45 | 2.42 | 2.03 | 2.38 | 1.75 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -29M | -30M | -43M | -52M | -34M | -27M |
| Operating Margin | 0.0% | -76.9% | -170.7% | -185.5% | -141.9% | -84.7% |
| ROE | -90.7% | -89.8% | -119.1% | -90.1% | -120.0% | -55.1% |
| Shares Outstanding | 12M | 1M | 1M | 1M | 1M | 1M |
PALVELLA THERAPEUTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PALVELLA THERAPEUTICS, INC. (PVLA) has a 5-year average return on invested capital (ROIC) of -89.3%. This is below average and may indicate limited pricing power.
PALVELLA THERAPEUTICS, INC. (PVLA) has a market capitalization of $1.5B. It is classified as a small-cap stock.
PALVELLA THERAPEUTICS, INC. (PVLA) does not currently pay a regular dividend.
PALVELLA THERAPEUTICS, INC. (PVLA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PALVELLA THERAPEUTICS, INC. (PVLA) reported annual revenue of $39 million in its most recent fiscal year, based on SEC EDGAR filings.
PALVELLA THERAPEUTICS, INC. (PVLA) has a net profit margin of -63.4%. The company is currently unprofitable.
PALVELLA THERAPEUTICS, INC. (PVLA) generated $-54 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PALVELLA THERAPEUTICS, INC. (PVLA) has a debt-to-equity ratio of 0.45. This indicates a conservatively financed balance sheet.
PALVELLA THERAPEUTICS, INC. (PVLA) reported earnings per share (EPS) of $-19.85 in its most recent fiscal year.
PALVELLA THERAPEUTICS, INC. (PVLA) has a return on equity (ROE) of -89.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for PALVELLA THERAPEUTICS, INC. (PVLA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PALVELLA THERAPEUTICS, INC. (PVLA) has a book value per share of $21.64, based on its most recent annual SEC filing.